Paper340441
The in vitro activity of apramycin, a new aminocyclitol antibiotic.
Ryden R and 1 other. J Antimicrob Chemother, 1977. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. The in vitro activity of apramycin, a new aminocyclitol antibiotic. Papers, record 340441. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/340441
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Bacteria | Major topic |
| Nebramycin | Major topic |
| Drug Resistance, Microbial | |
| Escherichia coli | |
| Microbial Sensitivity Tests | |
| Neomycin | |
| Streptomycin |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41471098 | Design, Synthesis, and Biological Evaluation of 6″-Modified Apramycin Derivatives to Overcome Aminoglycoside Resistance. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41471098 | PubMed |
| 37733880 | Biosynthetic Origin of the Octose Core and Its Mechanism of Assembly during Apramycin Biosynthesis. | J Am Chem Soc | 2023 | https://conductscience.org/library/papers/37733880 | PubMed |
| 34857778 | Intestinal microbiota modulation and improved growth in pigs with post-weaning antibiotic and ZnO supplementation but only subtle microbiota effects with Bacillus altitudinis. | Sci Rep | 2021 | https://conductscience.org/library/papers/34857778 | PubMed |
| 33007139 | An Advanced Apralog with Increased in vitro and in vivo Activity toward Gram-negative Pathogens and Reduced ex vivo Cochleotoxicity. | ChemMedChem | 2021 | https://conductscience.org/library/papers/33007139 | PubMed |
| 31790244 | Apralogs: Apramycin 5-O-Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltranserferase (3)-IV Resistance Determinant. | J Am Chem Soc | 2020 | https://conductscience.org/library/papers/31790244 | PubMed |
| 25136009 | In vivo efficacy of apramycin in murine infection models. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/25136009 | PubMed |
| 25071928 | New trends in aminoglycosides use. | Medchemcomm | 2014 | https://conductscience.org/library/papers/25071928 | PubMed |
| 22699498 | Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22699498 | PubMed |
| 7867728 | Urinary isolates of apramycin-resistant Escherichia coli and Klebsiella pneumoniae from Dublin. | Epidemiol Infect | 1995 | https://conductscience.org/library/papers/7867728 | PubMed |
| 3540112 | Apramycin and gentamicin resistance in Escherichia coli and salmonellas isolated from farm animals. | J Hyg (Lond) | 1986 | https://conductscience.org/library/papers/3540112 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/340441
GET https://conductscience.org/api/papers/v1/340441/authors